U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H33O8.Na
Molecular Weight 484.5155
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROCORTISONE SODIUM SUCCINATE

SMILES

C[C@@]12CCC(=O)C=C2CC[C@@]3([H])[C@]4([H])CC[C@](C(=O)COC(=O)CCC(=O)[O-])([C@@]4(C)C[C@@]([H])([C@@]31[H])O)O.[Na+]

InChI

InChIKey=HHZQLQREDATOBM-CODXZCKSSA-M
InChI=1S/C25H34O8.Na/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30;/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30);/q;+1/p-1/t16-,17-,18-,22+,23-,24-,25-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C25H33O8
Molecular Weight 461.5257
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008697s032_33lbl.pdf

Hydrocortisone is the main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). Hydrocortisone is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.

CNS Activity

Curator's Comment:: shown in dogs

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-5.38012811E11
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-5.38012811E11
Palliative
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-5.38012811E11
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-5.38012811E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
258 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1162 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.82 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
9.9%
HYDROCORTISONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 4 times / day multiple, intramuscular
Highest studied dose
Dose: 200 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, 56 years (tange: 40-64 years)
n = 10
Health Status: unhealthy
Condition: primary adrenal insufficiency
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Population Size: 10
Sources:
200 mg 4 times / day multiple, intravenous
Highest studied dose
Dose: 200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, 56 years (tange: 40-64 years)
n = 10
Health Status: unhealthy
Condition: primary adrenal insufficiency
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Population Size: 10
Sources:
200 mg 4 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 4 times / day
Route: oral
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, 56 years (tange: 40-64 years)
n = 10
Health Status: unhealthy
Condition: primary adrenal insufficiency
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Population Size: 10
Sources:
200 mg single, intravenous
Highest studied dose
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
unhealthy, 56 years (tange: 40-64 years)
n = 10
Health Status: unhealthy
Condition: primary adrenal insufficiency
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Population Size: 10
Sources:
2.5 % 4 times / day multiple, topical
Dose: 2.5 %, 4 times / day
Route: topical
Route: multiple
Dose: 2.5 %, 4 times / day
Sources:
unhealthy, adult
1 mg/kg 4 times / day multiple, intravenous
Dose: 1 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 4 times / day
Sources:
unhealthy, children
n = 23
Health Status: unhealthy
Condition: vasoactive infusion
Age Group: children
Population Size: 23
Sources:
Other AEs: Infection...
Other AEs:
Infection (below serious, 6 patients)
Sources:
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
n = 6
Health Status: unhealthy
Condition: Cardiovascular Insufficiency
Age Group: neonate
Population Size: 6
Sources:
Other AEs: Hyperbilirubinemia, Hypertension...
Other AEs:
Hyperbilirubinemia (serious, 1 patient)
Hypertension (serious, 1 patient)
Adrenal insufficiency (serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Infection below serious, 6 patients
1 mg/kg 4 times / day multiple, intravenous
Dose: 1 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 4 times / day
Sources:
unhealthy, children
n = 23
Health Status: unhealthy
Condition: vasoactive infusion
Age Group: children
Population Size: 23
Sources:
Adrenal insufficiency serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
n = 6
Health Status: unhealthy
Condition: Cardiovascular Insufficiency
Age Group: neonate
Population Size: 6
Sources:
Hyperbilirubinemia serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
n = 6
Health Status: unhealthy
Condition: Cardiovascular Insufficiency
Age Group: neonate
Population Size: 6
Sources:
Hypertension serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
n = 6
Health Status: unhealthy
Condition: Cardiovascular Insufficiency
Age Group: neonate
Population Size: 6
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Complications of lumbar puncture with injection of hydrosoluble material.
1999 Apr
The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers.
1999 Aug
RT-PCR quantification of AHR, ARNT, GR, and CYP1A1 mRNA in craniofacial tissues of embryonic mice exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin and hydrocortisone.
1999 Jan
Analysis of cytochrome P450 and phase II conjugating enzyme expression in adult male rat hepatocytes.
1999 Mar
Inducers of gamma-glutamylcysteine synthetase and their effects on glutathione synthetase expression.
2000 Sep 7
Endocrine and metabolic effects of insulin sensitizers in the treatment of patients with polycystic ovary syndrome and hyperinsulinaemia.
2001
Effect of ruminations on the saliva cortisol response to a social stressor.
2001 Apr
Enhanced memory for emotional material following stress-level cortisol treatment in humans.
2001 Apr
Individual differences in the diurnal cycle of salivary free cortisol: a replication of flattened cycles for some individuals.
2001 Apr
Lymphocyte responses to stress in postpartum women: relationship to vagal tone.
2001 Apr
Gender differences in age-related changes in HPA axis reactivity.
2001 Apr
Psychophysiological responses to the Stroop Task after a maximal cycle ergometry in elite sportsmen and physically active subjects.
2001 Feb
Circulatory support of the sick preterm infant.
2001 Feb
Interactions among paternal behavior, steroid hormones, and parental experience in male marmosets (Callithrix kuhlii).
2001 Feb
Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching.
2001 Feb
Plasma adrenocorticotropin and cortisol concentrations during acute hypoxemia after a reversible period of adverse intrauterine conditions in the ovine fetus during late gestation.
2001 Feb
PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells.
2001 Feb
Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2'-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke.
2001 Feb
Cord blood leptin and insulin-like growth factor levels are independent predictors of fetal growth.
2001 Feb
Human glucocorticoid feedback inhibition is reduced in older individuals: evening study.
2001 Feb
Troglitazone amplifies counterregulatory responses to hypoglycemia in nondiabetic subjects.
2001 Feb
Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
2001 Feb
Abnormalities in response to vasopressin infusion in chronic fatigue syndrome.
2001 Feb
Green fluorescent protein mutant as label in homogeneous assays for biomolecules.
2001 Feb 1
Hormonal regulation of mitochondrial Tim23 gene expression in the mouse mammary gland.
2001 Feb 14
Thapsigargin inhibits angiogenesis in the rat isolated aorta: studies on the role of intracellular calcium pools.
2001 Feb 16
Post-dexamethasone cortisol level and memory performance in elderly depressed patients.
2001 Feb 2
Inhibition of cortisol secretion in dispersed head kidney cells of rainbow trout (Oncorhynchus mykiss) by endosulfan, an organochlorine pesticide.
2001 Jan
Serum allopregnanolone in women with postpartum "blues".
2001 Jan
Net amino acid flux across the fetal liver and placenta during spontaneous ovine parturition.
2001 Jan
Growth hormone deficiency caused by pituitary stalk interruption in Fanconi's anemia.
2001 Jan
Back to basics: early diagnosis and compliance improve final height outcome in congenital adrenal hyperplasia.
2001 Jan
Adrenocortical dysfunction following etomidate induction in emergency department patients.
2001 Jan
Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus.
2001 Jan
Lower baseline plasma cortisol and prolactin together with increased body temperature and higher mCPP-induced cortisol responses in men with pedophilia.
2001 Jan
Neuroendocrine responses to experimentally-induced psychological stress in healthy humans.
2001 Jan
Circadian variation in O6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects.
2001 Jan 1
Altered levels of hypothalamic-pituitary-adrenocortical axis hormones in baboons and mice during the course of infection with Schistosoma mansoni.
2001 Jan 15
Crystallization of hydrocortisone acetate: influence of polymers.
2001 Jan 16
The use of chitosan gels as matrices for electrically-modulated drug delivery.
2001 Jan 29
Fetal hypothalamus-pituitary-adrenal axis on the road to parturition.
2001 Jan-Feb
Dynamics of circadian fluctuations in serum concentration of cortisol and TNF-alpha soluble receptors in gastrointestinal cancer patients.
2001 Jan-Feb
Patterns of integrin expression in a human mandibular explant model of osteoblast differentiation.
2001 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Many Hydrocortisone products are used topically https://www.drugs.com/pro/hydrocortisone.html
The initial dosage of CORTEF (Hydrocortisone) Tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated.
Route of Administration: Oral
Hydrocortisone concentration-dependently inhibited the current induced by 3 x 10(-5) M ACh with a half maximum inhibitory concentration (IC50) of 2.1 x 10(-4) M (in rats).
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:54:27 UTC 2021
Edited
by admin
on Fri Jun 25 20:54:27 UTC 2021
Record UNII
50LQB69S1Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROCORTISONE SODIUM SUCCINATE
MART.   ORANGE BOOK   USP   VANDF   WHO-DD   WHO-IP  
Common Name English
HYDROCORTISONE SODIUM SUCCINATE [VANDF]
Common Name English
HYDROCORTISONE SODIUM SUCCINATE [WHO-DD]
Common Name English
SOLU-CORTEF
Code English
A-HYDROCORT
Brand Name English
NSC-9152
Code English
HYDROCORTISONE SODIUM SUCCINATE [ORANGE BOOK]
Common Name English
CORTISOL 21-(SODIUM SUCCINATE)
Common Name English
HYDROCORTISONE SODIUM SUCCINATE [WHO-IP]
Common Name English
HYDROCORTISONI NATRII SUCCINAS [WHO-IP LATIN]
Common Name English
HYDROCORTISONE 21-SODIUM SUCCINATE
MI  
Common Name English
HYDROCORTISONE SODIUM SUCCINATE [MART.]
Common Name English
HYDROCORTISONE 21-SODIUM SUCCINATE [MI]
Common Name English
PREGN-4-ENE-3,20-DIONE, 21-(3-CARBOXY-1-OXOPROPOXY)-11,17-DIHYDROXY-, MONOSODIUM SALT, (11.BETA.)-
Common Name English
HYDROCORTISONE SODIUM SUCCINATE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C555
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
HYDROCORTISONE SODIUM SUCCINATE
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
PRIMARY Description: A white or almost white, crystalline powder or amorphous solid; odourless. Solubility: Freely soluble in water; soluble in 34 parts of ethanol (~750 g/l) TS and in 200 parts of dehydrated ethanol R; practically insoluble in ether R. Category: Adrenal hormone. Storage: Hydrocortisone sodium succinate should be kept in a tightly closed container, protected from light. Additional information: Hydrocortisone sodium succinate is hygroscopic. Even in the absence of light, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Hydrocortisone sodium succinate contains not less than 97.0% and not more than 103.0% of C25H33NaO8, calculated with reference to the dried substance.
RXCUI
235483
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL977
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
PRIMARY
FDA UNII
50LQB69S1Z
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
PRIMARY
PUBCHEM
23694214
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
PRIMARY
MERCK INDEX
M6094
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
PRIMARY Merck Index
EVMPD
SUB02569MIG
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
PRIMARY
NCI_THESAURUS
C1819
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
PRIMARY
DRUG BANK
DBSALT001297
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
PRIMARY
EPA CompTox
125-04-2
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
PRIMARY
CAS
125-04-2
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
PRIMARY
ECHA (EC/EINECS)
204-725-5
Created by admin on Fri Jun 25 20:54:27 UTC 2021 , Edited by admin on Fri Jun 25 20:54:27 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY